SARS-CoV-2 inhibitors

SARS-CoV-2 inhibitors refers to a drug discovery program managed by the Leuven Centre for Drug Design and Discovery (CD3) in collaboration with KU Leuven. This preclinical program is focused on the development of small molecule antiviral agents designed to inhibit essential viral proteins required for the replication of SARS-CoV-2, the virus responsible for COVID-19. While the specific molecular targets (such as the main protease Mpro or the RNA-dependent RNA polymerase) have not been explicitly disclosed for this particular pipeline entry, the program aims to identify potent compounds that can halt viral progression. The project leverages the medicinal chemistry and high-throughput screening expertise of CD3 alongside the virology research capabilities of the Rega Institute at KU Leuven.

Other names

SARS-CoV-2 inhibitor-Leuven Centre for Drug Design and Discovery-small molecule-COVID-19SARS-CoV2 inhibitor-Leuven Centre for Drug Design and Discovery-small molecule-COVID-19SARS-CoV 2 inhibitor-Leuven Centre for Drug Design and Discovery-small molecule-COVID-19